drugset / Trial / NCT07158411

Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2)

NCT07158411

Phase 1 Completed 22 enrolled Deciphera Pharmaceuticals, LLC
NaSequentialOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of multiple doses of vimseltinib on the pharmacokinetics (PK) of a clinical OCT2 substrate (metformin) in healthy male participants. This study will also assess the safety and tolerability when vimseltinib is co-administered with the clinical OCT2 substrate (metformin) in healthy male participants. This study will last approximately 25 days.

Timeline

Start
2025-11-20
Primary completion
2026-01-30
Completion
2026-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule Oral
Subject Vimseltinib Small molecule Oral

Indications

No indication recorded.